Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: a case report
(2020) Clinical Case Reports — (2020)
Files
2020_Percy_Clin_Case_Rep.pdf
Preprint
Open Access - Adobe PDF
- 191.12 KB
Details
- Authors
- Abstract
- NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK inhibitor larotrectinib is newly approved by the FDA. This paper reports the first case of a man with a NTRK-rearranged soft tissue sarcoma treated with larotrectinib in the neoadjuvant setting, in Belgium, to avoid limb amputation.
- Affiliations
Citations
Percy, C., Schubert, T., Galant, C., Kirchgesner, T., & Mazzeo, F. (2020). Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: a case report. Clinical Case Reports. Accepted/in-press. https://hdl.handle.net/2078.5/168249 (Original work published 2020)